Added to YB: 2025-12-12
Pitch date: 2025-12-10
MRK [bullish]
Merck & Co., Inc.
+19.6%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$280.2B
Pitch Price
$96.89
Price Target
122.00 (+5%)
Dividend
3.00%
EV/EBITDA
10.81
P/E
31.73
EV/Sales
4.92
Sector
Pharmaceuticals
Category
N/A
Institutional Alpha: Buying Calls in Merck & Co. (MRK)
MRK: Following $7M whale trade - 30k April '26 $110 calls bought at $2.39. Split-strike risk reversal: buy $110 calls, sell $85 puts for ~$0 net. Winrevair $8B peak sales potential, Keytruda resilience, pipeline depth. 200-day SMA support at $85, pullback to 21-day EMA entry. Guggenheim $122 PT.
Read full article (12 min)